- Home
- MIRA vs LSBPW Comparison
MIRA vs LSBPW Comparison
Compare MIRA & LSBPW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRA
- LSBPW
- Stock Information
- Founded
- MIRA 2020
- LSBPW N/A
- Country
- MIRA United States
- LSBPW China
- Employees
- MIRA N/A
- LSBPW 758
- Industry
- MIRA Biotechnology: Pharmaceutical Preparations
- LSBPW Biotechnology: Pharmaceutical Preparations
- Sector
- MIRA Health Care
- LSBPW Health Care
- Exchange
- MIRA Nasdaq
- LSBPW Nasdaq
- Market Cap
- MIRA 17.1M
- LSBPW N/A
- IPO Year
- MIRA 2023
- LSBPW N/A
- Fundamental
- Price
- MIRA $1.05
- LSBPW $0.07
- Analyst Decision
- MIRA Strong Buy
- LSBPW
- Analyst Count
- MIRA 2
- LSBPW 0
- Target Price
- MIRA $14.00
- LSBPW N/A
- AVG Volume (30 Days)
- MIRA 552.1K
- LSBPW N/A
- Earning Date
- MIRA 11-11-2024
- LSBPW N/A
- Dividend Yield
- MIRA N/A
- LSBPW N/A
- EPS Growth
- MIRA N/A
- LSBPW N/A
- EPS
- MIRA N/A
- LSBPW N/A
- Revenue
- MIRA N/A
- LSBPW N/A
- Revenue This Year
- MIRA N/A
- LSBPW N/A
- Revenue Next Year
- MIRA N/A
- LSBPW N/A
- P/E Ratio
- MIRA N/A
- LSBPW N/A
- Revenue Growth
- MIRA N/A
- LSBPW N/A
- 52 Week Low
- MIRA $0.51
- LSBPW N/A
- 52 Week High
- MIRA $6.40
- LSBPW N/A
- Technical
- Relative Strength Index (RSI)
- MIRA 38.97
- LSBPW N/A
- Support Level
- MIRA $1.04
- LSBPW N/A
- Resistance Level
- MIRA $1.20
- LSBPW N/A
- Average True Range (ATR)
- MIRA 0.07
- LSBPW 0.00
- MACD
- MIRA 0.02
- LSBPW 0.00
- Stochastic Oscillator
- MIRA 19.44
- LSBPW 0.00
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
About LSBPW LakeShore Biopharma Co. Ltd
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.